Clinical Effect of Albumin-bound Paclitaxel Combined with Cisplatin and Apatinib in the Treatment of Advanced Cervical Cancer

OBJECTIVE To observe the clinical efficacy, safety and economy of albumin-bound paclitaxel combined with cisplatin and apatinib in the treatment of advanced cervical cancer. METHODS Eighty-four patients with advanced cervical cancer treated in author's hospital from February 2018 to February 2019 were randomly divided into control group and observation group. Patients in the control group were treated with albumin-bound paclitaxel 175 mg·m^-2·d^-1+cisplatin 60 mg·m^-2·d^-1, and patients in the observation group were treated with apatinib 500 mg·d^-1 on the basis of the control group. Twenty one days treatment for 1 cycle. The efficiency, adverse reactions and ratio of cost-effectiveness were evaluated after 4 treatment cycles for 2 groups. Expression of serum CD3+, CD4+, CD8+ and NK cells were detected before and after treatment; serum expression levels of decoy receptor 3(DcR3) and Survivin were detected before and after the treatment; follow-ups were conducted after the treatment to evaluate the survival rate. RESULTS Eight patients(4 for each group) were departed during the research, so the number of patients of both groups were 38. The total remission rate of observation group(73.67%) was higher than that of control group(34.21%)(P<0.05). Serum CD3+, CD4+, CD4+/CD8+ and NK cells were decreased and CD8+ of 2 groups were increased after the treatment(P<0.05), and there was no significant difference between control group and observation group after the treatment. Serum DcR3 and Survivin were decreased after the treatment(P<0.05); the observation was lower as compared with control group(P<0.05). The survival rate of 6 months and 12 months of observation group were higher than that of control group(P<0.05). There was no significant difference of adverse reactions between two groups. CONCLUSION Albumin- bound paclitaxel combined with cisplatin and apatinib is effective in the treatment of advanced cervical cancer with controllable adverse reactions and low ratio of cost-effectiveness, which is worthy of clinical promotion.